To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyt...To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyte colony-stimulating factor(G-CSF),known for its ability to enhance the proliferation and differentiation of neutrophils,has been extensively employed for the prevention and treatment of neutropenia in various contexts.However,its application in patients with refractory/relapsing B-cell acute lymphoblastic leukemia(R/R B-ALL)after CAR-T cell therapy remains a topic of debate.[3]Several studies have suggested that G-CSF may exert anti-inflammatory effects by modulating the release of inflammatory factors,such as interleukin-12(IL-12),TNF-α,and IFN-γ,or by influencing the differentiation of T-cell subsets.[4]However,other researchers have posited that G-CSF could exacerbate cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS)through the augmentation of antigen-presenting cell function.展开更多
To the Editor:Chimeric antigen receptor(CAR)-T-cell therapy has made considerable breakthroughs in the treatment of lymphoma and myeloma,but the lack of suitable or specific targets for acute myelocytic leukemia(AML)h...To the Editor:Chimeric antigen receptor(CAR)-T-cell therapy has made considerable breakthroughs in the treatment of lymphoma and myeloma,but the lack of suitable or specific targets for acute myelocytic leukemia(AML)has limited the progress of CAR-T-cell therapy in the clinical treatment of AML.Cluster of differentiation(CD)312,a member of the adhesion G protein-coupled receptor family,is highly expressed in acute myeloid leukemia and absent in normal hematopoietic stem cells(HSCs),[1]making it a potential target antigen for CART-cell therapy.In this study,we assessed the expression of CD312 in AML cell lines and patients and constructed anti-CD312 CAR-T cells,which showed excellent antitumor activity and safety in vitro and in vivo.Notably,CD312 CAR-T cells exhibited no significant off-target effects,suggesting their potential as an effective and safe treatment strategy for AML.展开更多
Endometrial cancer(EC)is the sixth most common cancer in women worldwide,with an increasing incidence rate in China.Radiotherapy(RT)is important for the treatment of EC,especially for high risk or advanced stage tumor...Endometrial cancer(EC)is the sixth most common cancer in women worldwide,with an increasing incidence rate in China.Radiotherapy(RT)is important for the treatment of EC,especially for high risk or advanced stage tumors.The Brachytherapy Committee of China Anti-Cancer Association(CACA)organized relevant experts to develop this guideline and provide evidence-based RT recommendations tailored to China's epidemiological and clinical landscape.Highlighting key updates in molecular subtyping and the revised 2023 FIGO staging system,this portion of the CACA Guidelines for EC emphasizes personalized strategies across disease stages and details protocols for postoperative settings(radical resection,incomplete staging),recurrent/metastatic disease,and palliative care.By consolidating contemporary practices and regional data,this framework aims to standardize RT delivery,and improve survival outcomes while minimizing toxicities.We hope that this guideline will provide effective references for radiation oncologists,so as to achieve the best radiation treatment effects for EC patients in China.展开更多
基金supported by grants from the General Project of the National Natural Science Foundation of China(No.81970180)the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022QN030)+7 种基金the Key projects of Tianjin Applied Basic Research and Multi-Investment Fund(No.21JCZDJC01240)the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022XK018)Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-056B)Tianjin Municipal Natural Science Foundation(No.22JCQNJC00820)Tianjin Health Research Project(No.TJWJ2023QN027)Tianjin Health Bureau Project(No.ZC20074)Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJWJ2023XK010)Henan Provincial Youth and Middle-aged Health Science and Technology Talents Excellent Youth Program(No.20230273).
文摘To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyte colony-stimulating factor(G-CSF),known for its ability to enhance the proliferation and differentiation of neutrophils,has been extensively employed for the prevention and treatment of neutropenia in various contexts.However,its application in patients with refractory/relapsing B-cell acute lymphoblastic leukemia(R/R B-ALL)after CAR-T cell therapy remains a topic of debate.[3]Several studies have suggested that G-CSF may exert anti-inflammatory effects by modulating the release of inflammatory factors,such as interleukin-12(IL-12),TNF-α,and IFN-γ,or by influencing the differentiation of T-cell subsets.[4]However,other researchers have posited that G-CSF could exacerbate cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS)through the augmentation of antigen-presenting cell function.
基金supported by grants from the General Project of the National Natural Science Foundation of China(No.81970180)the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022QN030)+6 种基金the Key Projects of Tianjin Applied Basic Research and Multi-Investment Fund(No.21JCZDJC01240)the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022XK018)the Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-056B)the Tianjin Municipal Natural Science Foundation(No.22JCQNJC00820)the Tianjin Health Research Project(No.TJWJ2023QN027)the Tianjin Health Bureau Project(No.ZC20074)the Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJWJ2023XK010).
文摘To the Editor:Chimeric antigen receptor(CAR)-T-cell therapy has made considerable breakthroughs in the treatment of lymphoma and myeloma,but the lack of suitable or specific targets for acute myelocytic leukemia(AML)has limited the progress of CAR-T-cell therapy in the clinical treatment of AML.Cluster of differentiation(CD)312,a member of the adhesion G protein-coupled receptor family,is highly expressed in acute myeloid leukemia and absent in normal hematopoietic stem cells(HSCs),[1]making it a potential target antigen for CART-cell therapy.In this study,we assessed the expression of CD312 in AML cell lines and patients and constructed anti-CD312 CAR-T cells,which showed excellent antitumor activity and safety in vitro and in vivo.Notably,CD312 CAR-T cells exhibited no significant off-target effects,suggesting their potential as an effective and safe treatment strategy for AML.
基金Funding for this research was provided by Clinical Characteristic Technical Projects in Guangzhou Area(2023P‐TS26).
文摘Endometrial cancer(EC)is the sixth most common cancer in women worldwide,with an increasing incidence rate in China.Radiotherapy(RT)is important for the treatment of EC,especially for high risk or advanced stage tumors.The Brachytherapy Committee of China Anti-Cancer Association(CACA)organized relevant experts to develop this guideline and provide evidence-based RT recommendations tailored to China's epidemiological and clinical landscape.Highlighting key updates in molecular subtyping and the revised 2023 FIGO staging system,this portion of the CACA Guidelines for EC emphasizes personalized strategies across disease stages and details protocols for postoperative settings(radical resection,incomplete staging),recurrent/metastatic disease,and palliative care.By consolidating contemporary practices and regional data,this framework aims to standardize RT delivery,and improve survival outcomes while minimizing toxicities.We hope that this guideline will provide effective references for radiation oncologists,so as to achieve the best radiation treatment effects for EC patients in China.
